A randomized, double-blind, placebo-controlled parallel design Phase 2A study investigating the efficacy of PH10, a novel intranasal spray, in patients with major depressive disorder
Latest Information Update: 08 Nov 2024
At a glance
- Drugs Itruvone (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Pherin Pharmaceuticals
Most Recent Events
- 05 Nov 2024 According to a VistaGen media release, data from the study will be presented at the 2024 Neuroscience Education Institute (NEI) Congress in Colorado Springs, Colorado from November 7 to 10, 2024.
- 17 Jul 2023 Results presented in the VistaGen Therapeutics Media Release.
- 21 Jun 2023 Results of this trial assessing the efficacy and safety, presented in a VistaGen Therapeutics media release.